Macrogenics Inc. (MGNX)
The Schall Law Firm Is Conducting A Probe Into MacroGenics Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics Inc Is Under Investigation By The Schall Law Firm And Its Shareholders Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MGNX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your MacroGenics, Inc. investment
NEW YORK, NY / ACCESSWIRE / July 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Begins A Probe Into Claims Against MacroGenics Inc And Encourages Its Shareholders To Make Contact
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MGNX
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MGNX
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Begins A Probe Into Claims Against MacroGenics Inc And Motivates Its Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
Lost Money on MacroGenics, Inc.(MGNX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Initiates An Examination Of Accusations Against MacroGenics Inc And Urges Its Stakeholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on MacroGenics, Inc. (MGNX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
